FDA approves migraine drug
SPRINGFIELD, Ill. (WICS) —
A new FDA approved drug designed to fight chronic migraine attacks could be on the market within a week.
Aimovig is designed to reduce the frequency of migraines that affect about 12 percent of Americans.
The drug works by blocking the activity of a genetic molecule involved in migraine attacks.
Patients will be able to administer Aimovig through monthly injections at home.
The drug requires a prescription and it's expected to come with a price tag of $575 a month.